Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » Education » Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs

Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs

  • October 9, 2024

NECA have been involved in the development of Guidelines for “ Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs” which is now published and has been endorsed by the Commonwealth Neuroendocrine Tumour Collaboration and the North American Neuroendocrine Tumour Society.

After an extensive literature review, multidisciplinary in person workshop and Delphi methos  – the quality of evidence and strength of recommendations were determined using the Grading of Recommendations, Assessment, Development and Evaluations framework.  The study results suggest that select factors have sufficient evidence to inform care in GEP-NENs, but the evidence for most biomarkers is weak.

Read the Published article here along with the supplement

Share this post

Recent posts

BioPharmaDispatch 2025: Putting NETs on the National Agenda

May 27, 2025

WA Cancer Forum

May 27, 2025

ANZSNM 55th annual conference in Melbourne – Australia

May 27, 2025

NECA Strategy Day 2025

May 27, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPrevious12th INCA Global NET Cancer Advocate Summit
NextAUS-NET October 2024 updateNext

Related Posts

WA Cancer Forum

The Cancer Network WA, in collaboration with the WA Clinical Oncology Group at Cancer Council WA,  held its second annual one-day symposium “Cancer Network Forum

ANZSNM 55th annual conference in Melbourne – Australia

Thank you to Simone Leyden AM, Director Global Patient Advocacy and Government Affairs at Telix Pharmaceuticals Limited ARCS Australia, for organising sponsorship for a group

NECA Strategy Day 2025

On Wednesday 21 May, NeuroEndocrine Cancer Australia (NECA) hosted our annual Strategy Day in Sydney. It’s the one day each year when our entire team

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

NeuroEndocrine Cancer Australia (NECA) is proud to recognise the advocacy efforts of NET patient Chris Geljon, who has taken the time to raise awareness of

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin